Latest Breaking News On - Globe newswire cg oncology inc - Page 1 : comparemela.com

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in…

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in…
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Globe newswire cg oncology inc

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesVijay kasturiAmerican society of clinical oncologyGlobe newswire cg oncology incNon muscle invasive bladder cancerAmerican societyClinical oncologyChief medical officer

Cretostimogene Monotherapy Demonstrated 75 2% Complete Response Rate in High-Risk,

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy -

San antonioUnited statesAmbaw belleteLaurence wattsGaryd steinbergMarkd tysonCretostimogene grenadenorepvecCalmette guerinDrug administrationGlobe newswire cg oncology incAmerican urological associationNon muscle invasive bladder cancerBacillus calmette guerinPractice changing clinical trialsUrology plenary sessionUrologic oncologist

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients

San antonioUnited statesCalmette guerinLaurence wattsMarkd tysonCretostimogene grenadenorepvecHenryb gonzIntravesical cretostimogene grenadenorepvecGlobe newswire cg oncology incConvention centerAmerican urological associationAnnual meetingSingle arm studyHigh riskUnresponsive non muscle invasive bladder cancerPractice changing clinical trials

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeCalmette guerinCretostimogene grenadenorepvecVijay kasturiRoger liMccormick place convention centerGlobe newswire cg oncology incAmerican society of clinical oncologyCg oncology incAmerican societyClinical oncologyChief medical officerNon muscle invasive bladder cancerSitu abstract numberPrimary track